Buforin IIb induced cell cycle arrest in liver cancer

다국어 초록 (Multilingual Abstract)

The inhibitory effect of buforin IIb on different types of cancer, although not liver cancer, has been demonstrated previously. The aim of the present study was to investigate the effects of buforin IIb on the progression of liver cancer. The human liver cancer cell line HepG2 was treated with purified buforin IIb and the cell activity was determined by MTT, colony formation and transwell assays. The protein expression levels of cyclin-dependent kinases (CDKs) and cyclins were analyzed by western blotting and immunofluorescent cell staining. A tumor growth model was constructed using nude mice, and buforin IIb treatment was administered. The levels of CDK2 and cyclin A in the tumor tissues were detected by western blotting. Buforin IIb treatment depressed cell viability and colony formation and induced apoptosis significantly, and 1.0 μM concentration of buforin IIb was found to be the optimal dosage. The cell cycle was arrested at the G2/M phase following buforin IIb treatment. CDK2 and cyclin A were downregulated by treatment of the cells with 1.0 μM buforin IIb for 24 h. Treatment with buforin IIb also inhibited the migration of liver cancer cells in vitro. Furthermore, 50 nmol buforin IIb injection suppressed HepG2 cell subcutaneous tumor growth in the nude mouse model. Similar to the in vitro results, buforin IIb injection reduced the expression of CDK2 and cyclin A in the tumor tissue. these results demonstrate that buforin IIb inhibited liver cancer cell growth via the regulation of CDK2 and cyclin A expression.

참고문헌 (Reference)

1 Hoskin DW, "Studies on anticancer activities of antimicrobial peptides" 1778 : 357-375, 2008

2 Park CB, "Structureactivity analysis of buforin II, a histone H2A-derived antimicrobial peptide : The proline hinge is responsible for the cell-penetrating ability of buforin II" 97 : 8245-8250, 2000

3 Wulf J, "Stereotactic radiotherapy of primary liver cancer and hepatic metastases" 45 : 838-847, 2006

4 Lu S, "Regulation of androgen-dependent prostatic cancer cell growth : Androgen regulation of CDK2, CDK4, and CKI p16 genes" 57 : 4511-4516, 1997

5 Bosch FX, "Primary liver cancer : worldwide incidence and trends" 127 : S5-S16, 2004

6 Kasten MM, "PRb and the cdks in apoptosis and the cell cycle" 5 : 132-140, 1998

7 Lee HS, "Mechanism of anticancer activity of buforin IIb, a histone H2A-derived peptide" 271 : 47-55, 2008

8 Park CB, "Mechanism of action of the antimicrobial peptide buforin II : buforin II kills microorganisms by penetrating the cell membrane and inhibiting cellular functions" 244 : 253-257, 1998

9 Jang SA, "Mechanism of action and specificity of antimicrobial peptides designed based on buforin IIb" 34 : 283-289, 2012

10 Bruix J, "Management of hepatocellular carcinoma : An update" 53 : 1020-1022, 2011

11 Molenaar JJ, "Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells" 106 : 12968-12973, 2009

12 Lawrence TS, "Hepatic toxicity resulting from cancer treatment" 31 : 1237-1248, 1995

13 Cao QZ, "Ganoderma lucidum polysaccharides peptide inhibits the growth of vascular endothelial cell and the induction of VEGF in human lung cancer cell" 78 : 1457-1463, 2006

14 Wang Q, "Expression and purification of antimicrobial peptide buforin IIb in Escherichia coli" 33 : 2121-2126, 2011

15 Jang JH, "Enhancement of the cancer targeting specificity of buforin IIb by fusion with an anionic peptide via a matrix metalloproteinases-cleavable linker" 32 : 895-899, 2011

16 Jackman MR, "Cyclins and the G2/M transition" 29 : 47-73, 1997

17 Shapiro GI, "Cyclin-dependent kinase pathways as targets for cancer treatment" 24 : 1770-1783, 2006

18 Rivera A, "Cyclin A1 is a p53-induced gene that mediates apoptosis, G2/M arrest, and mitotic catastrophe in renal, ovarian, and lung carcinoma cells" 63 : 1425-1439, 2006

19 Malumbres M, "Cell cycle, CDKs and cancer : A changing paradigm" 9 : 153-166, 2009

20 Hancock RE, "Cationic peptides : Effectors in innate immunity and novel antimicrobials" 1 : 156-164, 2001

21 Baskar R, "Cancer and radiation therapy : current advances and future directions" 9 : 193-199, 2012

22 Yin F, "Apigenin inhibits growth and induces G2/M arrest by modulating cyclin-CDK regulators and ERK MAP kinase activation in breast carcinoma cells" 21 : 413-420, 2001

23 Meikrantz W, "Activation of cyclin A-dependent protein kinases during apoptosis" 91 : 3754-3758, 1994

24 Park CB, "A novel antimicrobial peptide from Bufo bufo gargarizans" 218 : 408-413, 1996